High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway

Figure 4

(a) Left: MMP-3 expression between normal tissue and the PDA tissue; Right: MMP-3 expression between normal PDA patients and the person with diabetes (DM) PDA patients (, ). (b) ROC curve of MMP-3 predicting the overall survival of PDA patients in 1-year, 3-years, and 5-years. AUC (area under the curve) measures the predicting efficacy of MMP-3 in different time models. (c) K-M survival plot of the high MMP-3 group, and the low MMP-3 group in the TCGA pancreatic cancer cohort (left) and TCGA PDA gemcitabine users (right). (d, e) GSEA analysis of pathways enriched in high MMP-3 group. (f) GO and KEGG analyses of the pathways enriched in high MMP-3 group. (g, h) Heat map of the association between the single genes (ENT1 (SLC29A1), ENT3 (SLC29A3), CNT1 (SLC28A1), CNT3 (SLC28A3), RRM1, RRM2, MRP1 (ABCB1), NOX1, NOX4, and PLK1) expression and the MMP-3 expression in PDA cohort (, ). (i) The expression of NOX4, RRM1, RRM2, CNT1, and CNT3 in 100 U MMP-3 treated pancreatic cancer cell line and normal control group from GSE50931 (ns: not significant (), ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)